9 results about "Evans Blue" patented technology

The present invention discloses a method for treating thyroid cancer using a radiolabeled cleavage-type Evans Blue degenerated fibroblast-activating protein inhibitor, said drug having excellent safety and tolerance in patients with thyroid cancer and having a very excellent therapeutic prospect in the treatment of thyroid cancer.

This invention provides a detection model for allergic reactions to Qingkailing injection. The model comprises seven modules: a mouse ear blue staining area percentage testing and data storage module; a mouse ear blue staining area scoring module; a mouse ear blue staining area result judgment module; a mouse ear tissue Evans blue (EB) exudate quantitative testing and data storage module; a mouse ear tissue Evans blue exudate calculation module; a mouse ear tissue Evans blue exudate result judgment module; and a result output module. The model provides clear evaluation and analysis methods and result judgment criteria, exhibiting a high detection reaction rate. At a dosage of 10 ml / kg, the reaction rate of Qingkailing injection reaches 100%, and the EB exudate amount is 6-10 times that of the negative control group. Furthermore, the method is simple to operate, less time-consuming, and has good repeatability, accurately and truthfully reflecting whether Qingkailing injection causes allergic reactions. This model has significant value and importance for the quality control, process research, and clinical application safety of Qingkailing injection.

This invention relates to the pharmaceutical field, specifically to the application of tissue inhibitor metalloproteinases-2 (TIMP2) in the preparation of drugs for the prevention or treatment of traumatic brain injury. TIMP2 protein can increase the fall latency in rotarod experiments in mice with traumatic brain injury; improve the motor balance ability of mice with traumatic brain injury on a balance beam; improve neurological function impairment in mice with traumatic brain injury; and reduce Evans blue permeability in brain tissue. In brain microvascular endothelial cells (HBMECs), TIMP2 protein can participate in maintaining the integrity of the endothelial barrier, reversing the loss of expression and altered localization of the connectome complex induced in an in vitro traumatic brain injury model, and reducing luciferase leakage. This invention also provides the application of TIMP2 protein as an Integrin α3β1 ligand in the preparation of drugs for the treatment of central nervous system diseases caused by blood-brain barrier dysfunction. TIMP2 protein exerts its function by binding to the cell membrane receptor Integrin α3β1, regulating VE-Cadherin phosphorylation. TIMP2 protein shows promising application prospects in the treatment of blood-brain barrier dysfunction caused by traumatic brain injury.

This invention discloses an Evans blue-modified nucleic acid aptamer targeting EpCAM, its preparation method, and its application. The Evans blue-modified nucleic acid aptamer EB-SYL3C is composed of SYL3C, a bifunctional chelating agent, and truncated Evans blue. Using EB-SYL3C as a ligand can prolong the blood circulation half-life of SYL3C, as well as improve tumor uptake and tumor retention time, thereby enabling its application in EpCAM-targeted radionuclide diagnosis or treatment.

The present application relates to a radiopharmaceutical aqueous solution and a use thereof. The radiopharmaceutical aqueous solution comprises a complex formed by a targeting molecule modified by an Evans blue (EB) fragment and a radioactive metal nuclide, as well as a stabilizer, the stabilizer preferably being one or two or more among gentisic acid, ethanol, and methionine.

The invention discloses an application of ginsenoside Ro in preparation of a medicine for treating cerebral ischemia-reperfusion injury. According to the application disclosed by the invention, by preparing a middle cerebral artery occlusion / reperfusion (MCAO) mouse model, the ginsenoside Ro is found to be capable of reducing the cerebral infarction volume of the model mouse, improving the pathological injury of brain tissues and increasing the cerebral blood flow at the ischemic side. Meanwhile, the ginsenoside Ro up-regulates the expression of brain tissue tight junction proteins ZO-1 and Occludin, inhibits the expression of matrix metalloproteinase MMP-9 / 2, reduces the leakage amount of Evans blue, and improves the blood brain barrier (BBB) dysfunction. Besides, by preparing an oxygen glucose deprivation / reperfusion (OGD / R) induced mouse brain microvascular endothelial cell line 3 (bEnd.3) cell model, it is found that the ginsenoside Ro can improve the damage of the barrier function of the bEnd.3 cell induced by the OGD / R, it is proved that the ginsenoside Ro can be used for the novel medical application of treating the cerebral arterial thrombosis, and the ginsenoside Ro has a wide application prospect.

The invention provides a method for detecting benzyl quaternary ammonium salt by using Evans blue, which comprises the following steps: mixing a sample to be detected with Evans blue to obtain a solution to be detected, detecting the solution to be detected by using ultraviolet-visible spectrophotometry, and calculating the content of benzyl quaternary ammonium salt in the sample to be detected according to the detection result and a standard curve. The Evans blue color development method provided by the invention can realize detection of the benzyl quaternary ammonium salt in a visible region, effectively avoids ultraviolet interference of other substances such as solvents, ions, small molecules and the like, can realize macroscopic rapid qualitative or semi-quantitative analysis, can realize quantitative analysis by virtue of a spectrophotometer, and has the advantages of high sensitivity and high sensitivity. The method has the advantages of being low in cost, easy and convenient to operate, high in analysis speed, good in accuracy, high in sensitivity and the like, trace benzyl quaternary ammonium salt components in a solution can be accurately determined, and a new thought is provided for detecting benzyl quaternary ammonium salt surfactants in a sewage environment.

The invention discloses a probe EB-PSMA-F as well as a preparation method and application thereof. Truncated Evans blue (EB) and a derivative of fluorophore IR820 are conjugated to a PSMA ligand to prepare the EB-PSMA-F probe, the probe has very high specific uptake in prostatic cancer, and due to the fact that the probe has the characteristics of long blood circulation half-life period and high tumor accumulation effect, a good imaging effect can be achieved with an extremely low dosage, and the probe has good application prospects. The fluorescent probe is a promising fluorescent probe. The EB-PSMA-F probe provided by the invention has the potential of being applied to optical real-time imaging in clinical prostatic cancer radical operation.